| Mechanisms of fatal opioid overdose JM White, RJ Irvine Addiction 94 (7), 961-972, 1999 | 799 | 1999 |
| Alpha2‐adrenergic agonists for the management of opioid withdrawal L Gowing, M Farrell, R Ali, JM White Cochrane Database of Systematic Reviews, 2016 | 508 | 2016 |
| The nature, time course and severity of methamphetamine withdrawal C McGregor, M Srisurapanont, J Jittiwutikarn, S Laobhripatr, T Wongtan, ... Addiction 100 (9), 1320-1329, 2005 | 456 | 2005 |
| Buprenorphine for the management of opioid withdrawal L Gowing, R Ali, JM White Cochrane Database of Systematic Reviews, 2009 | 439 | 2009 |
| The prevalence of alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in driver culpability: part ii: the relationship between drug … MC Longo, CE Hunter, RJ Lokan, JM White, MA White Accident Analysis & Prevention 32 (5), 623-632, 2000 | 415 | 2000 |
| Buprenorphine versus methadone maintenance therapy: a randomized double‐blind trial with 405 opioid‐dependent patients RP Mattick, R Ali, JM White, S O'Brien, S Wolk, C Danz Addiction 98 (4), 441-452, 2003 | 370 | 2003 |
| Hyperalgesic responses in methadone maintenance patients M Doverty, JM White, AA Somogyi, F Bochner, R Ali, W Ling Pain 90 (1-2), 91-96, 2001 | 365 | 2001 |
| Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10274), 605, 2021 | 321 | 2021 |
| Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial M Dennis, G Mead, J Forbes, C Graham, M Hackett, GJ Hankey, A House, ... The Lancet 393 (10168), 265-274, 2019 | 281 | 2019 |
| New psychoactive substances: challenges for drug surveillance, control, and public health responses A Peacock, R Bruno, N Gisev, L Degenhardt, W Hall, R Sedefov, J White, ... The Lancet 394 (10209), 1668-1684, 2019 | 259 | 2019 |
| Exposure to opioid maintenance treatment reduces long‐term mortality A Gibson, L Degenhardt, RP Mattick, R Ali, J White, S O'Brien Addiction 103 (3), 462-468, 2008 | 257 | 2008 |
| Buprenorphine for managing opioid withdrawal L Gowing, R Ali, JM White, D Mbewe Cochrane Database of Systematic Reviews, 2017 | 219* | 2017 |
| Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients JL Hay, JM White, F Bochner, AA Somogyi, TJ Semple, B Rounsefell The Journal of Pain 10 (3), 316-322, 2009 | 217 | 2009 |
| Opioid antagonists with minimal sedation for opioid withdrawal L Gowing, R Ali, JM White Cochrane Database of Systematic Reviews, 2017 | 210 | 2017 |
| Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine M Doverty, AA Somogyi, JM White, F Bochner, CH Beare, A Menelaou, ... Pain 93 (2), 155-163, 2001 | 208 | 2001 |
| Psychosocial treatment for methamphetamine use disorders: A preliminary randomized controlled trial of cognitive behavior therapy and acceptance and commitment therapy MF Smout, M Longo, S Harrison, R Minniti, W Wickes, JM White Substance abuse 31 (2), 98-107, 2010 | 203 | 2010 |
| Health status at entry to methadone maintenance treatment using the SF‐36 health survey questionnaire CF Ryan, JM White Addiction 91 (1), 39-45, 1996 | 191 | 1996 |
| Population drug use in Australia: a wastewater analysis RJ Irvine, C Kostakis, PD Felgate, EJ Jaehne, C Chen, JM White Forensic science international 210 (1-3), 69-73, 2011 | 190 | 2011 |
| Strength at the extracellular matrix–muscle interface MD Grounds, L Sorokin, J White Scandinavian journal of medicine & science in sports 15 (6), 381-391, 2005 | 185 | 2005 |
| Dose-related effects of alcohol on cognitive functioning MJ Dry, NR Burns, T Nettelbeck, AL Farquharson, JM White PloS one 7 (11), e50977, 2012 | 182 | 2012 |
